Logo

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

Share this

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

Shots:

  • The approvals is based on P-II UNITY-NHL trial involves assessing Ukoniq (800 mg- qd) in 69 patients with MZL who has received at least 1 prior anti-CD20 based regimen and in 117 patients with FL who received at least 2 prior systemic therapies
  • Results: ORR (49% vs 50%) as assessed by IRC- CR (16% vs 3.4%)- PR (33% vs 39%)- DoR of FL was 11.1 mos.
  • Ukoniq is the 1st oral inhibitor of PI3K delta and CK1 epsilon. Additionally- it has received BTD for MZL and ODD for MZL and FL

 ­ Ref: TG Therapeutics | Image: Seeking Alpha

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions